ALISO VIEJO, Calif.–(BUSINESS WIRE)–OCTANe, Orange County’s technology and life sciences accelerator organization, today announced that it has partnered with the CEDARS/ASPENS Society to enhance offerings around ophthalmic surgery for its annual Ophthalmology Technology Summit (OTS). OTS 2018 will be held June 29 at the Fashion Island Hotel in Newport Beach, California, bringing together a high-powered lineup of leading ophthalmology technologists, researchers, clinicians and entrepreneurs in
Category: Business
Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic solution) 0.02%
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye, today announced that it has launched Rhopressa® in the United States. Rhopressa® is now in national and regional U.S. pharmaceutical distributors, and patients have access to Rhopressa® through their local pharmaci
4DMT and ROCHE Expand Ophthalmology Partnership to Develop and Commercialize Multiple AAV Gene Therapy Products
EMERYVILLE, Calif.–(BUSINESS WIRE)–4D Molecular Therapeutics (4DMT), a leader in Therapeutic Vector Evolution for adeno-associated virus (AAV) gene therapy vector discovery and product development, today announced the expansion of its 2016 research a…
North America Fiber Optic Gyroscope Market Segmented By Sensing Axis, Device, Application, Geography & Company Landscape – Analysis, Trends & Forecast To 2025 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “North America Fiber Optic Gyroscope Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2025” report has been added to ResearchAndMarkets.com’s offering. The North America fiberoptic gyroscope …
Ocular Therapeutix™ to Report First Quarter 2018 Financial Results
BEDFORD, Mass.–(BUSINESS WIRE)–Ocular Therapeutix™, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will report first quarter ended March 31, 2018 financial results on Tuesday, May 8, 2018. Following distribution of the earnings release via wire services, the Ocular Therapeutix management team will host a live conference call and webcast at 4:
Global Retinal Drugs Market – Development of Innovative Therapies to Boost Growth | Technavio
LONDON–(BUSINESS WIRE)–#RareDiseases–Technavio’s latest market research report on the global retinal drugs market provides an analysis of the most important trends and drivers.
Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8, 2018
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its first quarter 2018 financial results will be released after the market closes on Tuesday, May 8, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company’s website at htt
Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8, 2018
DURHAM, N.C.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its first quarter 2018 financial results will be released after the market closes on Tuesday, May 8, 2018. Following the release, the Company will host a live conference call and webcast at 5:00 p.m. Eastern Time to discuss the Company’s financial results and provide a general business update. The live webcast and a replay may be accessed by visiting the Company’s website at htt
BioTime to Announce First Quarter 2018 Results on May 10, 2018
ALAMEDA, Calif.–(BUSINESS WIRE)–BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will release first quarter 2018 financial and operating results on Thursday, May 10, 2018, after the close of the U.S. financial markets. The Company will host a conference call and webcast on Thursday, May 10, 2018, at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time to discuss the results and recent corporate developments. The co
Guardion Health Sciences to Present at Planet Microcap Showcase 2018 Las Vegas
SAN DIEGO,Calif.–(BUSINESS WIRE)–Guardion Health Sciences to Present at Planet Microcap Showcase 2018 Las Vegas
Graybug Vision Announces Presentations on Novel Treatments for Wet AMD and Glaucoma at ARVO 2018 Annual Meeting
REDWOOD CITY, Calif.–(BUSINESS WIRE)–Graybug Vision Announces Presentations on Novel Treatments for Wet AMD and Glaucoma at ARVO 2018 Annual Meeting
MeiraGTx Announces AAV-RPGR Granted Fast Track Designation by U.S. FDA for Treatment of X-Linked Retinitis Pigmentosa Due to RPGR Deficiency
LONDON & NEW YORK–(BUSINESS WIRE)–MeiraGTx Limited, a vertically integrated, clinical stage gene therapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for AAV-RPGR for the treatment of X-linked retinitis pigmentosa (XLRP) due to defects in the retinitis pigmentosa GTPase regulator (RPGR) gene. “XLRP is a devastating condition that causes rapid progression to blindness and currently has no approved treatment options. This Fast Trac
Additional Clinical Studies Supporting the Benefits of OMIDRIA® Presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) announced that the results of four real-world clinical studies evaluating the benefits of OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% were presented at the American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting held in Washington, D.C., April 13-17, 2018. The studies examined the use of OMIDRIA in both routine and complex cataract surgery cases perf
Ophthalmology Pipeline Database 2018: Conjunctivitis, Glaucoma, Diabetic Retinopathy, Myasthenia Gravis, Dry Eye Syndrome, Age-related Macular Degeneration, and Cataract – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Ophthalmology Pipeline Database – 2018” report has been added to ResearchAndMarkets.com’s offering. Ophthalmology Pipeline Highlights Database – 2018, provides most up-to-date information on key pipeline products in the gl…
Global Dry Eye Pipeline Highlights 2018-2020 – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Dry Eye Pipeline Highlights – 2018” report has been added to ResearchAndMarkets.com’s offering. Dry Eye Pipeline Highlights – 2018 provides most up-to-date information on key pipeline products in the global Dry eye market….
Global Vision Care Market – Innovative Product Launches to Boost Growth | Technavio
LONDON–(BUSINESS WIRE)–#Health–Technavio’s latest market research report on the global vision care market provides an analysis of the most important trends and drivers.
IDE Pivotal Trial Results for Glaukos’ iStent inject® Show Significant Reductions in Unmedicated IOP in Glaucoma Subjects Undergoing Cataract Surgery
SAN CLEMENTE, Calif. & WASHINGTON–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma, today announced that two-year U.S. Investigational Device Exemption (IDE) pivotal trial data showed that its iStent inject® Trabecular Micro-Bypass System achieved a statistically significant reduction in unmedicated diurnal intraocul
Global Diabetic Eye Disease Devices Market – Latest Developments by Technavio
LONDON–(BUSINESS WIRE)–#MedicalDevices–Market research firm Technavio has announced the release of their latest report on the global diabetic eye disease devices market for 2018-2022.
Global Cataract Surgical Devices Market 2018-2023 – IOLs are the Most Popular Product Type – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Cataract Surgical Devices Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2018-2023” report has been added to ResearchAndMarkets.com’s offering. According to the report, the global cataract su…
Omeros Corporation Announces Upcoming Presentations of New Data on OMIDRIA® at the American Society of Cataract and Refractive Surgery Meeting
SEATTLE–(BUSINESS WIRE)–Omeros Corporation (NASDAQ: OMER) today announced that the results of four studies directed to the benefits of OMIDRIA across a range of clinical situations in cataract surgery will be presented at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) Congress in Washington, D.C., April 13-17, 2018. The four presentations are scheduled as follows: Saturday, April 14: 1:41 PM – 1:46 PMWalter E. Washington Convention Center – Room 143AMiosis Prevention